Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03364803
Other study ID # 17-592
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 28, 2017
Est. completion date November 28, 2024

Study information

Verified date October 2023
Source Memorial Sloan Kettering Cancer Center
Contact Eliza Geer, MD
Phone 646-888-2627
Email geere@mskcc.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date November 28, 2024
Est. primary completion date November 28, 2024
Accepts healthy volunteers No
Gender All
Age group 14 Years and older
Eligibility Inclusion Criteria: - Age 14 or older - Active or treated Cushing's (due to pituitary, ectopic, or adrenal tumor) - The diagnosis of CS will be made by the PI, based on the below Endocrine Society guidelines, the patient's clinical presentation, and the PI's judgment. ° Diagnostic criteria for pituitary CD are according to the Endocrine Society guidelines and include: Elevated 24-hour urinary free cortisol (UFC), normal or elevated plasma ACTH, elevated midnight salivary cortisol levels, or classic dexamethasone suppression testing for CD (morning cortisol > 5 ug/dL after 1 mg overnight of classic 2-day low dose test) and a pituitary lesion on MRI. If patient does not have any of these results, pathology of ACTH tumor may confirm presence of disease. - For pituitary patients, if the patient demonstrates non-classic testing or no pituitary lesion is seen on MRI then petrosal sinus sampling or positive surgical pathology will be used to confirm pituitary source of Cushing's. Clinical or biochemical remission after surgery will also confirm pituitary source. - Ectopic Cushing's will be confirmed by petrosal sinus sampling and appropriate imaging tests, or positive surgical pathology. - Adrenal Cushing's will be confirmed by a suppressed plasma ACTH value and identification of an adrenal lesion on CT or MRI, or positive surgical pathology. - In lieu of MRI, surgical, or laboratory reports, physician's assessment note including mention of results will also be used as source for eligibility purposes. Exclusion Criteria: - Patients with a diagnosis of iatrogenic Cushing's.

Study Design


Intervention

Other:
Cushing's QoL (Quality of Life Questionnaire)
Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
Nottingham Health Profile (NHP)
NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
Hospital Anxiety and Depression Scale (HADS)
HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
Perceived Stress Scale (PSS)
The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
Barratt's Impulsivity Scale (BIS)
BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
Beck Depression Inventory (BDI)
BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
State-Trait Anxiety Inventory (STAI)
The STAI provides data to help distinguish between anxiety and depression.
State Food Craving Questionnaire-State (FCQ-S)
The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
Trait Food Craving Questionnaire-Trait (FCQ-T)
Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
Visual Analogue Scale (VAS)
A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption ("How much do you think you can eat?"), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark.
Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey
United States Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity) Commack New York
United States Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York
United States Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center New York New York
United States Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Collection of data on Cushing's Syndrome participants before and over time after surgical, medication, and/or radiation therapy. up to 10 years after treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT05881005 - NAC- NAFLD And Cushing N/A
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Terminated NCT03379363 - Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Recruiting NCT06008184 - Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
Recruiting NCT05911620 - Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism N/A
Completed NCT02934399 - Dynamic Hormone Diagnostics in Endocrine Disease
Recruiting NCT04045015 - Liquorice and Salivary Cortisol N/A
Recruiting NCT05804669 - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome Phase 1/Phase 2
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting NCT03343470 - The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
Terminated NCT02001051 - Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Phase 2
Completed NCT03697109 - A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Phase 3
Enrolling by invitation NCT03604198 - Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Phase 2
Completed NCT05347979 - Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants Phase 1
Recruiting NCT01382420 - Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma N/A
Completed NCT00001849 - New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Phase 2
Recruiting NCT06229405 - Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
Recruiting NCT03211624 - Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
Terminated NCT05456997 - Metabolic Myopathy in Endocrinopathy